Ginwa Enterprise GroupSHSE:600080 -1.20%47 EBITDA Margin % is 3.52% as of Mar. 2026, which is 66% below its 10-year median of 10.40. GuruFocus rates SHSE:600080 with a GF Score™ of 47/100 and a GF Value™ of ¥7.53 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 956 Drug Manufacturers companies, Ginwa Enterprise Group ranks worse than 68.41% on this metric.
Ginwa Enterprise Group (SHSE:600080) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ginwa Enterprise Group EBITDA Margin % Related Terms
Ginwa Enterprise Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ginwa Enterprise Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600080 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ginwa Enterprise Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginwa Enterprise Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ginwa Enterprise Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ginwa Enterprise Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginwa Enterprise Group (SHSE:600080) has a EBITDA Margin % of 3.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ginwa Enterprise Group and its competitors. This is 66% below median its historical median of 10.40. Over the past decade, Ginwa Enterprise Group's EBITDA Margin % has ranged from 0.23 to 13.62. According to the industry distribution chart, Ginwa Enterprise Group ranks #654 out of 956 companies in the Drug Manufacturers industry, placing it in the top 68.4%.
Is Ginwa Enterprise Group's EBITDA Margin % too high?
Ginwa Enterprise Group's current EBITDA Margin % of 3.52% is 66% below median its 10-year median of 10.40. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 13.62. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Ginwa Enterprise Group's value of 3.52% is 71.9% below this industry median. Based on the distribution chart, Ginwa Enterprise Group ranks #654 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ginwa Enterprise Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ginwa Enterprise Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ginwa Enterprise Group ranks #654 out of 956 companies for EBITDA Margin %. This places Ginwa Enterprise Group in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Ginwa Enterprise Group's value of 3.52% is 71.9% below this benchmark. Historically, Ginwa Enterprise Group's own EBITDA Margin % has ranged from 0.23 to 13.62 over the past decade. While the company's 10-year median is 10.40 vs. the industry median of 12.52, Ginwa Enterprise Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginwa Enterprise Group's current EBITDA Margin % of 3.52% is 71.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ginwa Enterprise Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginwa Enterprise Group's current EBITDA Margin % is 3.52%, which is 66% below median its own 10-year median of 10.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginwa Enterprise Group stock overvalued right now?
Based on GuruFocus' analysis, Ginwa Enterprise Group (SHSE:600080) is currently considered Possible Value Trap. The stock's GF Value™ is ¥7.53, compared to a current price of ¥4.94 — trading 34.4% below its estimated fair value. The current EBITDA Margin % is 3.52%, which is 66% below median its 10-year median of 10.40 and 71.9% below the Drug Manufacturers industry median of 12.52. Ginwa Enterprise Group's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ginwa Enterprise Group (SHSE:600080), the current EBITDA Margin % is 3.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginwa Enterprise Group (SHSE:600080) Overvalued in 2026?
Based on GuruFocus' analysis, Ginwa Enterprise Group stock appears to be undervalued.
The current stock price of ¥4.94 is trading 34.4% below its estimated GF Value™ of ¥7.53.
GuruFocus considers Ginwa Enterprise Group to be Possible Value Trap.
Key valuation signals for SHSE:600080:
EBITDA Margin %: 3.52% (66% below median its 10-year median of 10.40)
GF Value™: ¥7.53 vs. price of ¥4.94 (34.4% below fair value)
Industry Position: 71.9% below the Drug Manufacturers median (#654 of 956)
No single metric tells the full story. See the SHSE:600080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
47GF Score
Get the complete analysis for SHSE:600080
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600080 has been successfully added to your 
